qol improvement after cardioversion of persistent af (qol-cafrct)

Conditions: Atrial Fibrillation

Summary: atrial fibrillation (af) is a type of irregular heart rhythm due to electrical signal disturbances of the heart. it is a very common arrhythmia and the risk of developing af increases with age and with other risk factors such as diabetes, high blood pressure, and underlying heart disease. the main complications of af are heart failure and stroke. however, studies have shown that restoration of normal rhythm does not reduce these complications. rather, these complications are mitigated by controlling the heart rate and using blood thinners to prevent stroke. symptoms secondary to af can occur due to the irregular heart rate and poor contraction in the atria, the top chambers of the heart. these symptoms include shortness of breath, fatigue, reduced exercise tolerance, and palpitations. restoring sinus rhythm can sometimes alleviate these symptoms. given that studies to date have not shown a difference in hard clinical endpoints between rate and rhythm control strategies, the decision to proceed with rhythm control depends on the patient symptom burden. rhythm control strategies in patients with persistent af include cardioversion back to sinus rhythm with long-term recurrence prevention via anti-arrhythmic drugs (aads) or catheter ablation. however, many studies of these procedures omit a sham placebo control arm. no atrial fibrillation procedural intervention has been compared to a sham procedure. the cardioversion procedure can easily be compared to a "sham" alternative, as it is non-invasive with an expected response within days-to-weeks. thus, a cardioversion versus "sham" cardioversion trial will allow us to truly assess the impact of a rhythm-control strategy on qol. it is hypothesized that cardioversion of atrial fibrillation leads to significant improvement in quality of life (qol) compared to sham cardioversion. understanding the true qol impact of sinus rhythm restoration in patients with persistent af is of significant importance in guiding strategies for the management of af. hence, by evaluating what the true effect of cardioversion on qol in this blinded study, we can better understand the role of medical management and af ablation in our patients and assess resource allocation to these procedures.

the study is a prospective, randomized, single-blinded, sham-controlled trial. all recruited patients will undergo a 4-week pre-cardioversion phase of medical optimization (including anticoagulation assessment/initiation, initiation of amiodarone at 200mg daily, and rate-control medications targeting a resting heart rate of \<100 bpm). an activity monitor is provided to patients to be worn during waking hours for nine days. a baseline echocardiogram is also performed (if not available within previous 6 months) during this pre-cardioversion phase. one day prior to the day of cardioversion, the patient will have a 12-lead ecg. if the patient is in sinus rhythm (chemical cardioversion due to amiodarone) they will be exited from the study and referred back to their mrp cardiologist. if the patient is in af, they will be randomized electronically using web-based software (dacima, montreal, canada) to "shock" or "sham shock". this will not be revealed to investigators and will be put in a closed envelope and questionnaires will be administered. during the day of the cardioversion procedure, following anaesthesia administration, the unblinded team (non-mrp cardiologist / anesthesiologist will open the envelope indicating which arm the patient has been randomized to. other members of the team will step out of the room. the unblinded non-mrp cardiologist will call out as per usual "all clear", following which a shock is delivered as per the ottawa cardioversion protocol in the "shock" arm. otherwise, no shock is delivered in the "sham shock" arm. following the intervention, telemetry is discontinued by the unblinded team prior to patient restoration of consciousness. the unblinded team in the day unit will refrain from providing the patient with information regarding which arm they were randomized to. for the purpose of the patient chart and related documentation, a standardized template will be provided to document the process but not the actual intervention, as to maintain patient blinding. a patch holter monitor is to be applied and worn for rest of study (4 weeks). after 4 weeks post-cardioversion, a blinded healthcare professional will re-administer a series of questionnaires. at the end of the trial (4 weeks), an ecg will be performed and the patients will be unblinded and told their results. a follow-up (telephone or in-person) will be undertaken at 6 weeks with the patients' mrp cardiologist for discussion of further treatment.

Eligibility criteria:
inclusion criteria: * patients age ≥ 18 years * persistent atrial fibrillation * unknown symptom burden related to af exclusion criteria: * known left-atrial appendage thrombus * prior catheter or surgical ablation for af * intolerance or contraindication to amiodarone * contraindication to appropriate anticoagulation * patient is included in another randomized clinical trial * patient is unable or unwilling to provide informed consent * patient with a history of noncompliance with medical therapy * patient does not meet all of the above listed inclusion criteria * pregnancy (all women of child bearing age and potential will have a negative bhcg test before enrolment) * breastfeeding * patients for whom the investigator believes that the trial is not in the interest of the patient

Keywords: quality of life improvement electrical cardioversion sham cardioversion rhythm control placebo